Hypolipidemic effects of a novel neutracheutical containing monacolin K, combined with coenzyme Q10, policosanols, Bergamot and thistle extract in patients with mild dyslipidemia.

icholaos Angelopoulos,MD,Phd0 个研究点目标入组 80 人开始时间: 2023年5月19日最近更新: 2024年5月21日

适应症

试验速览

Asignificant median reduction of 13.25% in LDL-C levels was achieved in the treated group and no adverse effects were reported.

•Patients are eligible to participate in the present study if they have mild hypercholesterolemia (fasting LDL-C concentration between 140 and 180 mg/dL) and no indication for statin treatment [10-year atherosclerotic cardiovascular disease risk (ASCVD Risk) < 7.5%]. The 10-year risk wil be calculated in all participants using the updated ASCVD Risk Estimator Plus (found in: https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate

•Use of lipid-lowering medications, such as statins, within 3 months prior to study enrollment, conditions which produce an increased ASCVD risk, such as diabetes mellitus, known atherosclerotic vascular disease, or moderate/severe renal insufficiency (Modification of Diet in Renal Disease calculated glomerular filtration rate, MDRD GFR < 60 mL/min), abnormal liver function tests, excessive alcohol intake, pregnancy, lactation or the use of oral contraceptives

发起方

icholaos Angelopoulos,MD,Phd